how regulatory barriers inhibit pharmaceutical competition : field hearing of the Subcommittee on Children and Families of the Committee on Health, Education, Labor, and Pensions, United States Senate, One Hundred Fourteenth Congress, second session on examining EpiPen price increases, focusing on how regulatory barriers inhibit pharmaceutical competition, October 7, 2016 (Lexington, KY) United States Congress. Senate. Committee on Health, Education, Labor, and Pensions. Subcommittee on Children and Families, creator text bibliography Legislative hearings. dcu 2018 monographic eng 1 online resource (iii, 43 pages) : illustrations. CRDP Program record. Includes bibliographical references. n-us--- Prescription pricing United States Drugs Law and legislation United States Pharmaceutical industry United States Competition United States Drug delivery devices Prices United States KF26 .L2733 2016 Y 4.L 11/4:S.HRG.114-805 Y 4.L 11/4:S.HRG.114-805 United States. Congress. Senate. Committee on Health, Education, Labor, and Pensions. Subcommittee on Children and Families. (OCoLC)1078409593 United States. Congress. Senate. https://purl.fdlp.gov/GPO/gpo113215 https://purl.fdlp.gov/GPO/gpo113215 PUCPR 181214 20190121092913.0 on1078951640 eng